Susanne Bobadilla from VML Health, joined by a team of 15 medical, digital strategists and client engagement experts from across the company, looks at the top trends coming out of ESMO 2024 and what ...

The data was still under wraps at that time, but has just been revealed in the ESMO congress abstract drop – a 3.2 month improvement over control, compared to 1.6 months at ASCO. Taken in ...

“ESMO 2022 had really outstanding sessions for ... those who are HRD-positive […] and those who are HRD-negative, meaning that they are homologous recombination proficient in their tumour ...

Completed Pre-Biologics License Application (BLA) meeting with the U.S. Food and Drug Administration (FDA) and remain on track to submit a BLA ...

On the outside, the process can seem a little random or opaque, but every Emoji inclusion is the result of careful examination regarding its meaning. The Unicode Consortium has seven criteria that ...

Positive clinical data with confirmed overall response rate (ORR) = 62.5% (95% CI, 30.4-86.5) and prospective ACR-368 OncoSignature patient ...

Here you will find news stories and blog posts about the research our scientists have presented at the congress over the years. ESMO Virtual Plenary 2022: Major trial shows targeted drug improves ...

Good morning and welcome to Agenus' third quarter 2024 conference call and webcast. All participants will be in a listen-only ...

Before we begin, I'd like to remind listeners that comments made during this call by management will include forward-looking ...

November 6, 2024Personalis, Inc. misses on earnings expectations. Reported EPS is $-0.64 EPS, expectations were $-0.33.

Merus’ zenocutuzumab is nearing FDA approval, and petosemtamab shows promise. Learn why MRUS stock could rise as the company ...

Expects to deliver three Investigational New Drug (IND) applications in next three years based on next-generation ADC <a target=_blank href=http ...